Serum Markers of Collagen Turnover Predict Future Shocks in Implantable Cardioverter-Defibrillator Recipients With Dilated Cardiomyopathy on Optimal Treatment

Journal of the American College of Cardiology

Volumn 55, Issue 24, 2010, Pages 2753-2759

  Kanoupakis, Emmanuel M ^a   Manios, Emmanuel G ^a   Kallergis, Eleftherios M ^a   Mavrakis, Hercules E ^a   Goudis, Christos A ^a   Saloustros, Ilias G ^a   Milathianaki, Maria E ^a   Chlouverakis, Gregory I ^b   Vardas, Panos E ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

collagen; defibrillators; fibrosis; ventricular arrhythmias

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CARBOXY TERMINAL TELOPEPTIDE; CARVEDILOL; COLLAGEN DERIVATIVE; COLLAGEN TYPE 1 C TERMINAL PROPEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIAC PATIENT; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DEFIBRILLATOR; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; COLLAGEN; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; DISEASE PROGRESSION; ELECTRIC COUNTERSHOCK; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROGNOSIS; PROSTHESIS DESIGN; RISK FACTORS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 77953109129     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.02.040     Document Type: Article

References (30)

1. Bansch D., Antz M., Boczor S., et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 105 (2002) 1453-1458
2. Strickberger S.A., Hummel J.D., Bartlett T.G., et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol 41 (2003) 1707-1712
3. Kadish A., Dyer A., Daubert J.P., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 (2004) 2151-2158
4. Bardy G.H., Lee K.L., Mark D.B., et al., Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
5. Epstein A.E., DiMarco J.P., Ellenbogen K.A., et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). J Am Coll Cardiol 51 (2008) e1-e62
6. Richardson P.J. Assessment of myocardial damage in dilated cardiomyopathy. Eur Heart J 17 (1996) 489-490
7. Marijianowski M.M., Teeling P., Mann J., and Becker A.E. Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: a quantitative assessment. J Am Coll Cardiol 25 (1995) 1263-1272
8. Gunja-Smith Z., Morales A.R., Romanelli R., and Woessner Jr. J.F. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline crosslinks. Am J Pathol 1448 (1996) 1639-1648
9. Wu T.J., Ong J.J., Hwang C., et al. Characteristics of wave fronts during ventricular fibrillation in human hearts with dilated cardiomyopathy: role of increased fibrosis in the generation of reentry. J Am Coll Cardiol 32 (1998) 187-196
10. Lopez B., Gonzalez A., Varo N., Laviades C., Querejeta R., and Dýez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 38 (2001) 1222-1226
11. Zannad F., Alla F., Dousset B., Perez A., and Pitt B. Limitation of extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Insights from the RALES study. Circulation 102 (2000) 2700-2706
12. Klappacher G., Franzen P., Haab D., et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 75 (1995) 913-918
13. Host N.B., Jensen L.T., Bendixen P.M., Jensen S.E., Koldkjaer O.G., and Simonsen E.E. The aminoterminal propeptide of type III procollagen provide new information on prognosis after acute myocardial infarction. Am J Cardiol 76 (1995) 869-873
14. Lijnen P., Petrov V., and Fagard R. Induction of cardiac fibrosis by transforming growth factor-b1. Mol Genet Metab 71 (2000) 418-435
15. Li Y.Y., McTiernan C.F., and Feldman A.M. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 46 (2000) 214-224
16. Goldberger J.J., Cain M.E., Hohnloser S.H., et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. J Am Coll Cardiol 52 (2008) 1179-1199
17. Zecchin M., Di Lenarda A., Gregori D., et al. Are nonsustained ventricular tachycardias predictive of major arrhythmias in patients with dilated cardiomyopathy on optimal medical treatment?. Pacing Clin Electrophysiol 31 (2008) 290-299
18. Grimm W., Christ M., Bach J., Müller H.H., and Maisch B. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation 108 (2003) 2883-2891
19. Zankovic V., Karha J., Passman R., Kadish A.H., and Goldberger J.J. Predictors of appropriate implantable cardioverter-defibrillator therapy in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 89 (2002) 1072-1076
20. Gillis A.M., Sheldon R.S., Wyse D.G., Duff H.J., Cassidy M.R., and Mitchell L.B. Clinical and electrophysiologic predictors of ventricular tachyarrhythmia recurrence in patients with implantable cardioverter defibrillators. J Cardiovasc Electrophysiol 14 (2003) 492-498
21. Weber K.T., Anversa P., Armstrong P.W., et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 20 (1992) 3-16
22. Cohn J.N., Ferrari R., and Sharpe N. Cardiac remodeling: concepts and clinical implications: a consensus paper from international forum on cardiac remodeling. J Am Coll Cardiol 35 (2000) 569-582
23. Tyagi S.C., Kumar S.G., Banks J., and Fortson W. Co-expression of tissue inhibitor and matrix metalloproteinase in myocardium. J Mol Cell Cardiol 27 (1995) 2177-2189
24. Silver M.A., Pick R., Brilla C.G., Jalil J.E., Janicki J.S., and Weber K.T. Reactive and reparative fibrillar collagen remodeling in the hypertrophied rat left ventricle: two experimental models of myocardial fibrosis. Cardiovasc Res 24 (1990) 741-747
25. Akar F.G., Spragg D.D., Tunin R.S., Kass D.A., and Tomaselli G.F. Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res 95 (2004) 717-725
26. Schwartzkopff B., Fassbach M., Pelzer B., Brehm M., and Strauer B.E. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 4 (2002) 439-444
27. Ohtsuka T., Nishimura K., Kurata A., Ogimoto A., Okayama H., and Higaki J. Serum matrix metalloproteinase-3 as a novel marker for risk stratification of patients with nonischemic dilated cardiomyopathy. J Card Fail 13 (2007) 752-758
28. Timonen P., Magga J., Risteli J., et al. Cytokines, interstitial collagen and ventricular remodelling in dilated cardiomyopathy. Int J Cardiol 124 (2008) 293-300
29. Blangy H., Sadoul N., Dousset B., et al. Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction. Europace 9 (2007) 724-729
30. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321